Background and objective Immune checkpoint inhibitors (ICIs) and antibody-drug
conjugates (ADCs) herald a transformative era in metastatic renal cell carcinoma (RCC) and …

Purpose To analyze and summarize the efficacy of immune checkpoint inhibitor (ICI) alone
or in combination therapy for renal cell carcinoma (RCC) and urothelial carcinoma (UC) …

Background There is an ongoing debate as to whether sex could be associated with
immune checkpoint inhibitor (ICI) benefit. Existing literature data reveal contradictory results …

Background Renal c carcinoma (RCC) is one of the most common urinary cancers
worldwide, with a predicted increase in incidence in the coming years. Immunotherapy, as a …

Background Recent years have witnessed the advent of novel treatment options for
metastatic renal cell carcinoma (mRCC), including combination therapies with immune …

Context There have been substantial changes in the management of patients with metastatic
renal cell carcinoma (mRCC) over the past decade, with upfront immunotherapy-based …

Recent meta-analyses on checkpoint inhibitors in cancer report conflicting data regarding
the association of patient gender with inhibitor efficacy. In advanced kidney cancer …

Several first-line immune-checkpoints inhibitors (ICI) based combinations have been studied
in metastatic renal cell carcinoma (mRCC) without any direct comparison between the …

Background. Sex, age, and International Metastatic Renal‐Cell Carcinoma Database
Consortium (IMDC) prognostic risk may influence the immune response. Nonetheless, the …

The last three decades have witnessed a revolution in the therapeutic scenario of metastatic
renal cell carcinoma (mRCC), due to the advent of novel agents including tyrosine kinase …